Qianjin Pharmaceutical Profit Jumps 42% on New Drug Approvals and Procurement Wins
Four products win national procurement slots through 2029 Four Qianjin products — dydrogesterone, iguratimod, baricitinib and alogliptin tablets — were tentatively selected in China's 12th national drug bulk-buy. That locks in guaranteed sales volume to end-2029, giving the company a steadier, more predictable revenue base and supporting the share price.
This is the biggest new commercial event, securing multi-year sales volume for four products.
Five new drug approvals expand product line Subsidiaries won registration certificates for Baclofen tablets plus minoxidil liniment, ezetimibe tablets, amlodipine benazepril capsules and ursodeoxycholic acid capsules. These add fresh revenue streams, though each is small today — Baclofen's whole China market was only 247 million yuan in 2025.
New product approvals are the pipeline that feeds future growth, a core reason the stock is being re-rated.
First-half profit up 41.6%, fifth straight year of growth H1 revenue rose 5.5% to 1.918 billion yuan while net profit jumped 41.6% to 181 million yuan, with second-quarter revenue up 16.6%. Operating cash flow more than tripled. Profit growing far faster than sales shows better margins and cost control, a strong signal for the shares.
The interim results are the single clearest evidence of improving profitability and cash generation.
Dividend of 1.8 yuan per 10 shares planned Management proposed a cash dividend of 1.8 yuan per 10 shares, about 88.6 million yuan total — roughly half of first-half profit returned to shareholders. A solid payout signals confidence in cash flow and gives income-focused investors a reason to hold the stock.
The dividend is a concrete capital return that supports valuation and investor confidence.